Abstract 5840
Background
Pembrolizumab is used routinely in advanced NSCLC. Combination strategies, such as with RT are of great interest. We report on safety and tolerability of an open-label phase 1 trial for cohort 1 of pembrolizumab with 2 schedules of palliative RT.
Methods
All cohort 1 patients started with a pembrolizumab dose of 100mg given 2 weeks prior to RT, and then received pembrolizumab 100mg 2-weekly concurrently with RT, followed by maintenance dose 200mg pembrolizumab 3-weekly. The RT was either 20 Gy/5# (low dose RT - LD) or 36 Gy/12# (high dose RT - HD). Cohort 2 pembrolizumab dose will be 200mg, for all doses, with the same RT schedules. Dose limiting toxicity (DLT) period, 2 months from completing RT, is defined as grade (G) 2 pneumonitis, G4 oesophagitis or G2 myelitis.
Results
3/6 pts in the LD and 6/8 pts in the HD were evaluable for DLTs. Mean age was 61 years, 64% were female, 71% were smokers, ECOG performance status was 1 in 100%. 57% were of non-squamous histology with no driver mutations, and 64% were PD-L1 positive (TPS ≥1%). All pts had adverse events (AEs); G3–4 AEs were seen in 66.7% in the LD and 37.5% in the HD. There were no DLTs. In the LD, G3 AEs included: anaemia (n = 1), back pain (n = 1), bronchitis (n = 1), dyspnoea (n = 1), fatigue (n = 1), hypokalaemia (n = 1), hypophosphataemia (n = 1), and syncope (n = 2). In the HD, 1 pt had drug induced liver injury (G1 ALT, G3 ALP, G2 AST, G1 bilirubin, G4 GGT), and so the cohort was expanded by a further 3 pts. No DLTs were seen. G3 AEs included: pneumonia (n = 1), back pain (n = 1), dehydration (n = 1), radiation dermatitis (n = 1), diarrhoea (n = 1), hyperglycaemia (n = 1), and hypokalaemia (n = 2). 1 pt had G4 urosepsis. In the LD and HD, pts also had RT dermatitis (G1 n = 11, G2 n = 2), RT esophagitis (G1 n = 10, G2 n = 4), and RT pneumonitis (G1 n = 6). With a median follow-up of 7.9 months, median PFS was 1.3 months in the LD and 3.7 months in the HD (HR 0.28, P = 0.056). Median OS was 5.2 months in the LD and 8.3 months in the HD (HR 0.59, P = 0.441). Disease control rate (DCR) was 37.5% in the LD (3 SD) and 62.5% in the HD (3 PR, 2 SD; P = 0.592). DCR did not correlate with PD-L1 status (P = 1.00).
Conclusions
Combining pembrolizumab and palliative thoracic RT appears to be safe and tolerable with both RT doses. This trial continues to recruit to cohort 2.
Clinical trial identification
NCT NCT02587455.
Legal entity responsible for the study
Royal Marsden Clinical Trials Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, United Kingdom.
Funding
Merck Sharp Dohme.
Editorial Acknowledgement
There was no editorial assistance sort.
Disclosure
R. Kumar, A. Tree, S. Lalondrelle: Research grants: MSD. D.P. Walder: Research grants: BMS. J. Bhosle: Honoraria: BMS; Travel grants: BMS. S. Popat: Honoraria: MSD and BMS. F. McDonald, K. Harrington, R. Huddart: Research grants and Honoraria: MSD. M.E.R. O’Brien: Research grants: MSD; Honoraria: MSD and BMS. M. Ahmed: Research grants: MSD and BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract